Analyst Price Targets — CARL
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 15, 2026 12:25 pm | — | Truist Financial | $18.00 | $10.80 | TheFly | Carlsmed price target lowered to $18 from $20 at Truist |
| January 9, 2026 10:49 am | — | Goldman Sachs | $20.00 | $12.87 | TheFly | Carlsmed price target raised to $20 from $19 at Goldman Sachs |
| December 15, 2025 10:54 am | Ryan Zimmerman | BTIG | $24.00 | $12.95 | StreetInsider | BTIG Reiterates Buy Rating on Carlsmed Inc (CARL) |
| August 18, 2025 8:49 am | Matt O'Brien | Piper Sandler | $18.00 | $13.58 | TheFly | Carlsmed initiated with an Overweight at Piper Sandler |
Latest News for CARL
Carlsmed (NASDAQ: CARL) used its presentation at Needham's 25th Annual Healthcare Conference to highlight progress in its patient-specific digital surgery platform, recent clinical outcomes data, and evolving reimbursement landscape as it expands from lumbar into cervical spine fusion. Personalized spine fusion platform and market expansion CEO Mike Cordonnier described Carlsmed as a "digital-first" medtech company…
CARLSBAD, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today announced it will report its first quarter 2026 financial results after market close on Tuesday, May 5, 2026.
Carlsmed (NASDAQ: CARL - Get Free Report) and MiniMed Group (NASDAQ: MMED - Get Free Report) are both manufacturing companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation and analyst recommendations. Institutional and Insider Ownership 19.7% of MiniMed Group shares
CARLSBAD, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced that Mike Cordonnier, CEO and Chairman, will be presenting at the 25th Annual Needham Virtual Conference on April 13, 2026 at 11:45 AM ET.
Carlsmed (NASDAQ: CARL - Get Free Report) and Predictive Oncology (NASDAQ: AGPU - Get Free Report) are both small-cap manufacturing companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, earnings, institutional ownership, analyst recommendations, risk and profitability. Analyst Recommendations This is a summary of recent
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CARL.
U.S. House Trading
No House trades found for CARL.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.